Heineken warns weight-loss drugs could reduce UK beer sales
Weight-loss medications such as Ozempic and Wegovy could reduce consumer demand for beer and cider in British drinking establishments, brewer Heineken warned UK pubs this month. While major brewers have largely debated the market impact of GLP-1 receptor agonists, the Netherlands-headquartered company sent a presentation to British hospitality customers outlining how widespread medication use could curb traditional drinking sessions.
- GLP-1 receptor agonist medications, including Ozempic and Wegovy, are increasingly associated by users with a reduced desire to consume alcohol.
- Hospitality businesses are advised to adapt their offerings toward half-pints, low- and zero-alcohol options, and premium selections.
British Pubs Face Declining Pints as GLP-1 Use Expands
The global brewing giant warned that the surging popularity of anti-obesity treatments could disrupt traditional hospitality sales patterns. According to research by JPMorgan cited across industry reports, approximately 10 million people used GLP-1 medications in the United States last year. Heineken noted that these treatments often leave users feeling a sense of fullness and result in fewer serves per customer visit. Beer generated nearly £14 billion of sales in British pubs, bars, and restaurants in the year leading up to February 2026, with less than £300 million of that total coming from no- and low-alcohol products, according to a Heineken UK report.
GLP-1 Medications Reduce the Desire to Drink Alcohol
GLP-1 medications can reduce the desire to drink alcohol and influence consumption behaviour among users. Joseph Schacht, a professor, noted that GLP-1 effects on the brain may alter a user’s motivation to drink alcohol. Ten out of eleven GLP-1 users interviewed by Reuters reported reducing their alcohol consumption, sometimes significantly. Participants stated that drinking alcohol left them feeling uncomfortable, unwell, or stripped of their desire to partake. Daniel Cornwell, founder of hospitality executive recruitment business SPE Resourcing, reported that alcohol now causes physical discomfort and severe hangovers, shifting his habits away from workplace and weekend drinking events.
GLP-1 Users Reduce Monthly Alcohol Spending
Alcohol manufacturers remain divided on the long-term impact of anti-obesity medications on consumer spending. Market research firm Circana tracked a group of US households with a GLP-1 user between 2024 and 2026, finding that these households reduced monthly alcohol spending by about 7% compared to non-using households, including a 13.5% decrease in beer purchases. Surveys conducted by market researchers NIQ and KAM also pointed to reduced drinking among users. Conversely, major spirits maker Diageo informed investors that any broader market impact from mainstream GLP-1 adoption should remain manageable. Carlsberg told Reuters that existing data did not yet support the conclusion that weight-loss drugs were driving overall beer consumption trends, while Anheuser-Busch InBev declined to comment on the matter.
Hospitality Adaptations Planned for 2027
Heineken urged venue operators to promote half-pints, low- and zero-alcohol beverages, and small-plate food pairings to mitigate potential drops in customer spending. The brewer stated that GLP-1 users are not abandoning alcohol entirely but are instead becoming more intentional in their choices, favoring smaller serves and premium products. “We see some changes in consumption behaviour among (GLP-1) users and will continue to monitor how these behaviours evolve in 2027,” a Heineken spokesperson stated. The company added that the presentation was part of regular engagement with UK businesses to help them understand broader consumer shifts toward health, wellness, and moderation.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.